Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Stavraka C, Pouptsis A, Synowiec A, Angelis V, Satterthwaite L, Khan S, Chauhan M, Holden C, Young S, Karampera C, Martinou M, Mills-Baldock T, Baxter M, Barry A, Eccles B, Iveson T, Shiu KK, Hill M, Abdel-Raouf S, Graham JS, Thomas A, Ross PJ. Stavraka C, et al. Among authors: eccles b. Clin Colorectal Cancer. 2021 Dec;20(4):342-349. doi: 10.1016/j.clcc.2021.09.009. Epub 2021 Sep 26. Clin Colorectal Cancer. 2021. PMID: 34696965
Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study.
Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Lawrence G, Jones L, Bliss J, Eccles D; POSH Study Steering Group. Copson E, et al. Among authors: eccles b, eccles d. J Natl Cancer Inst. 2013 Jul 3;105(13):978-88. doi: 10.1093/jnci/djt134. Epub 2013 May 30. J Natl Cancer Inst. 2013. PMID: 23723422
Genetic and immune landscape evolution in MMR-deficient colorectal cancer.
Challoner BR, Woolston A, Lau D, Buzzetti M, Fong C, Barber LJ, Anandappa G, Crux R, Assiotis I, Fenwick K, Begum R, Begum D, Lund T, Sivamanoharan N, Sansano HB, Domingo-Arada M, Tran A, Pandha H, Church D, Eccles B, Ellis R, Falk S, Hill M, Krell D, Murugaesu N, Nolan L, Potter V, Saunders M, Shiu KK, Guettler S, Alexander JL, Lázare-Iglesias H, Kinross J, Murphy J, von Loga K, Cunningham D, Chau I, Starling N, Ruiz-Bañobre J, Dhillon T, Gerlinger M. Challoner BR, et al. Among authors: eccles b. J Pathol. 2024 Feb;262(2):226-239. doi: 10.1002/path.6228. Epub 2023 Nov 15. J Pathol. 2024. PMID: 37964706
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators; Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, Nathan … See abstract for full author list ➔ Corrie PG, et al. Among authors: eccles b. Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229. Ann Oncol. 2018. PMID: 30010756 Free PMC article. Clinical Trial.
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, Rao A, Fusi A, Danson S, Eccles B, Carser J, Brown CO, Steven N, Bhattacharyya M, Brown E, Gonzalez M, Highley M, Pickering L, Kumar S, Waterston A, Burghel G, Demain L, Baker E, Wulff J, Qian W, Twelves S, Middleton M, Corrie P. Dayimu A, et al. Among authors: eccles b. Eur J Cancer. 2024 Jan;196:113455. doi: 10.1016/j.ejca.2023.113455. Epub 2023 Nov 24. Eur J Cancer. 2024. PMID: 38029480 Free article. Clinical Trial.
Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study.
Copson E, Maishman T, Gerty S, Eccles B, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Jones L, Tapper W; POSH study steering group; Eccles D. Copson E, et al. Among authors: eccles b, eccles d. Br J Cancer. 2014 Jan 7;110(1):230-41. doi: 10.1038/bjc.2013.650. Epub 2013 Oct 22. Br J Cancer. 2014. PMID: 24149174 Free PMC article.
Obesity and the outcome of young breast cancer patients in the UK: the POSH study.
Copson ER, Cutress RI, Maishman T, Eccles BK, Gerty S, Stanton L, Altman DG, Durcan L, Wong C, Simmonds PD, Jones L, Eccles DM; POSH Study Steering Group. Copson ER, et al. Among authors: eccles bk, eccles dm. Ann Oncol. 2015 Jan;26(1):101-112. doi: 10.1093/annonc/mdu509. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361993 Free article.
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM. Copson ER, et al. Among authors: eccles b. Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11. Lancet Oncol. 2018. PMID: 29337092 Free PMC article.
20 results